2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 954

Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 538

Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Abstract Number: 819

Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Abstract Number: 536

Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
Abstract Number: 550

Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Abstract Number: 2944

Sedentary Time Is an Independent Risk Factor for Disability Onset Among Adults at Elevated Risk: Prospective Cohort Study
Abstract Number: 1513

Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
Abstract Number: 267

Selective and Peripheral-Specific Trk Inhibitor Shows Potent Analgesic Effect Comparable to Morphine in Rat Osteoarthritis Model without CNS Toxicity
Abstract Number: 2184

Selective Consumption of C2 Component in HCV Patients
Abstract Number: 391

Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer
Abstract Number: 173

Self-Management Education for Patients with Gout: A Review of Existing Resources
Abstract Number: 2164

Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of ‘anti-inflammatory’ Myeloid-Derived Suppressor Cells (MDSC)
Abstract Number: 2663

Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus
Abstract Number: 2142

Sensitivity and Precision of Automated Osteophyte Volumetric Measurement in Knee Osteoarthritis over Four Years
Abstract Number: 2129

Sensitivity and Specificity of the “Green Nail” Sign in Fluorescence Optical Imaging in Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].